text_1: Drug for Immune Disorders Helps Alzheimer’s
text_2: "The biggest weakness was its failure to put the study results into any meaningful context for readers. It describes points on a symptom scale without telling us the significance of these changes. And it describes slowing the rate of brain shrinkage in what sound like impressive terms but without giving any context for readers to fully grasp whether it’s truly impressive or not. We applaud the independent perspective sought from the Mayo Alzheimer’s expert and its reminder – ""In the past few years alone, several Alzheimer’s drugs that made it to this stage failed to pan out in further testing."""